<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00914797</url>
  </required_header>
  <id_info>
    <org_study_id>TER2009JE</org_study_id>
    <nct_id>NCT00914797</nct_id>
  </id_info>
  <brief_title>Terbutaline Concentrations in Blood and Urine</brief_title>
  <official_title>Blood and Urinary Concentrations of Terbutaline in Asthmatics and Elite Athletes With Asthma: Comparison Between Inhalation vs. Oral Administration.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hormone Laboratory, Aker University Hospital, Oslo, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the blood and urine concentrations of terbutaline and
      to evaluate the difference between inhaled and oral terbutaline in order to distinguish
      treatment with terbutaline from doping with terbutaline in a doping control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the serum and urine concentrations of terbutaline and evaluate the difference
      between inhaled terbutaline (2 mg) and oral terbutaline (10 mg) in order to distinguish
      doping with terbutaline from anti-asthmatic treatment with terbutaline.

      To investigate the above mentioned in three groups: healthy men, male asthmatic subjects and
      male elite athletes with asthma.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Terbutaline concentrations in serum and urine</measure>
    <time_frame>baseline, 4, 8, and 12 hours after medicine administration</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>asthmatics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 male asthmatic subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 male healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>elite athletes with asthma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 elite athletes with asthma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled and oral terbutaline</intervention_name>
    <description>Inhalation of 2 mg terbutaline as powder as a single dosage. Oral terbutaline 10 mg as a single dosage.
Inhaled: Bricanyl Turbohaler 0.5 mg/dose, MA no. 41076.
Oral: Tablet Bricanyl Retard 5 mg, MA no. 10954.</description>
    <arm_group_label>asthmatics</arm_group_label>
    <arm_group_label>healthy</arm_group_label>
    <arm_group_label>elite athletes with asthma</arm_group_label>
    <other_name>Bricanyl Turbohaler 0.5 mg/dose, MA no. 41076.</other_name>
    <other_name>Tablet Bricanyl Retard 5 mg, MA no. 10954.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physician-diagnosed asthma with positive reversibility or challenge test.

          -  Informed consent.

          -  Age between 18 - 45 years.

          -  Sex: male.

          -  Asthma classified as mild to moderate according to GINA guidelines.

          -  Used beta-2-agonist in minimum 12 months.

        Exclusion Criteria:

          -  Smokers or ex-smokers with a smoking history of 10 pack years or more.

          -  Respiratory tract infections within the last 2 weeks prior to visit 1 and 2.

          -  Subjects with other chronic diseases than asthma and allergy.

          -  Allergy towards the study medicine.

          -  Use of beta-2-agonist 6 days prior to study day.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jimmi Elers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital, Respiratory Research Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jimmi ElersÂ½, MD</last_name>
    <phone>+45 35313208</phone>
    <email>jele0004@bbh.regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bispebjerg Hospital, Respiratory Research Unit</name>
      <address>
        <city>Kobenhavn NV</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jimmi Elers, MD</last_name>
      <phone>+45 35313208</phone>
      <email>jele0004@bbh.regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Jimmi Elers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2009</study_first_submitted>
  <study_first_submitted_qc>June 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2009</study_first_posted>
  <last_update_submitted>June 4, 2009</last_update_submitted>
  <last_update_submitted_qc>June 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jimmi Elers</name_title>
    <organization>Respiratory Research Unit, Bispebjerg Hospital</organization>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Doping</keyword>
  <keyword>Beta agonist</keyword>
  <keyword>Terbutaline</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terbutaline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

